logo

European Medicines Agency remains cautious toward pioglitazone, but hesitates to issue outright ban despite Actos bladder cancer evidence

(Oct. 25, 2011)  After earlier sending signals that it might move to outlaw the drug pioglitazone (Actos), the European Medical Agency backed off last week from recommending any such ban on the grounds that Type 2 diabetics who respond only to this particular pharmaceutical should not lose access to it, despite mounting evidence linking Actos to bladder cancer.

The EMA announced Oct. 21 that, because some patients cannot be adequately treated by other treatments, pioglitazone should remain available as a treatment option.

However, the agency at the same time refused to rescind its July issuance of new warnings and contraindication recommendations for the drug.

Those warnings came in response to findings linking pioglitazone to a small increased risk of bladder cancer.

“Risk factors for bladder cancer should be assessed before initiating pioglitazone treatment,” the agency said in a news release. “Prescribers are advised not to use these medicines in patients with current or a history of bladder cancer or in patients with uninvestigated macroscopic haematuria.

“In light of age-related risks, the balance of benefits and risks should be considered carefully both before initiating and during treatment in the elderly.

“Prescribers should review the treatment of patients on pioglitazone after three to six months (and regularly afterwards) to ensure that only patients who are deriving sufficient benefit continue to take it.”

The EMA conceded there exists a need for further analysis of the types, evolution and severity of bladder cancer in patients treated with pioglitazone compared to diabetics treated without it.

The EMA’s updated recommendation next will be sent to the European Commission for a vote.

Pioglitazone marketed under the brand name Actos was authorized for sale in the European Union in 2000. The drug is made by Takeda Pharmaceutical Co., based in Osaka, Japan. It has been the subject of litigation in the U.S. since the Actos-bladder cancer link came to light.

Latest News from Pharma-Watch

FDA convenes to determine Fosamax bone fracture dangers

The New York Times Reports: In light of evidence linking the long-term use of Fosamax and femur fractures, the FDA said it plans to convene Friday to determine whether it will recommend suspending the use of the osteoporosis drug.

Spine Specialists Discredit Medtronic Bone Growth Product

June 29th, 2011 “It harms patients to have biased and corrupted research published…It harms patients to have unaccountable special interests permeate medical research,” read an excerpt from an

CT Brain Perfusion Scan Risks

The FDA released an advisory to consumers in October regarding the CT Bran Profusion Scan manufactured by GE. The advisory states that the scans default radiation therapy is set to high for most patient

Risk of death found in sleeping pill use -- Scripps

Scripps Study: Sleeping pills believed a cause of 500,000 premature deaths annually (March 1, 2012) Pick 10 people at random and ask them if they take sleeping pills. Chances are at least one of them

FDA pulls approval of Avastin breast cancer drug

Avastin no longer allowed for breast cancer The U.S. Food & Drug Administration has revoked its approval of Avastin after concluding the metastatic breast cancer treatment did nothing to control tumor